News | Nuclear Imaging | April 21, 2016

UltraSPECT Celebrates 10th Anniversary of Wide Beam Reconstruction Technology Approval

Company says technology for ultra-low dose, ultra-fast nuclear imaging has helped drive sales

UltraSPECT, 10th anniversary, WBR technology, Wide Beam Reconstruction, FDA approval, nuclear imaging

April 21, 2016 – UltraSPECT Inc. announced the 10th anniversary of the U.S. Food and Drug Administration (FDA) approval of its Wide Beam Reconstruction (WBR) technology. The technology employs an iterative reconstruction imaging algorithm to enable lower dose and shorter time imaging for nuclear medicine exams.

An early entrant to the market, UltraSPECT has had double-digit growth in both annual revenue and annual units sold for the last few years. Factors like the recently introduced American Society of Nuclear Cardiology (ASNC) low-dose guidelines, heightened patient awareness to the risks of exposure to radiation, and new Centers for Medicare and Medicaid Services (CMS) reimbursement penalties have accelerated the quest by hospitals to implement emerging low-dose and ultra-low dose nuclear medicine technologies. 

In 2006, UltraSPECT introduced to the U.S. market the first application for shorter-time patient imaging both for oncology and cardiology exams, and followed that with the enhanced technology for both shorter-time and lower-dose imaging in 2008. The resulting benefit is enhanced value to physicians, technologists, patients, administrators and radiopharmaceutical suppliers of reduced dose, shorter scans and increased patient comfort with images as good, if not better in diagnostic quality, than those provided with traditional single photon emission computed tomography (SPECT) acquisition.

UltraSPECT has achieved the following key milestones:

  • Double-digit revenue growth for the past three years;
  • More than 200 units sold between 2013-2015;
  • Installations in 46 states;
  • 16 distribution partners, including 8 different radiopharmaceutical pharmacies;
  • Compatibility with 41 different gamma cameras and 12 workstations representing all the major manufacturers; and
  • 100% field validation

“What started as a handful of installations have evolved into tremendous market demand as everyone — from patients and technologists to physicians, pharmacies and pharmacy staff — is benefiting,” said Wayne Wong, owner and vice president, Nuclear Diagnostic Products. “We believed in the product from the beginning and trusted that the nuclear medicine would catch on to the low-dose movement, and being an early partner of UltraSPECT has been a great decision for us.”

While early adopters were instrumental in setting the foundation for UltraSPECT, recent expansion has been in part due to a number of other market conditions, including changes from regulatory groups. They include the ASNC guidelines for low-dose imaging that took effect in January 2015, along with the Physician Quality Reporting System (PQRS) requirement to obtain an additional 2 percent in CMS reimbursement. Other industry pressures influencing the market are:

  • Growing shortage of Tc-99m isotope;
  • Greater awareness by patients of the need for low-dose imaging supported, in part, by action groups like Image Wisely, launched at the Radiological Society of North America (RSNA) 2010 annual meeting; and
  • Growing cost pressures. At a fraction of the cost of a brand-new camera, UltraSPECT also provides one of the most cost-effective solutions to the nuclear medicine market, according to the company.

For more information: www.ultraspect.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...